Talking to Patients with Multiple Sclerosis About Anti-CD20 Therapies


Ahmed Obeidat, MD, PhD, and Riley Bove, MD, review strategies for how to make drug classes and the risks-benefits profiles of individual agents accessible to patients.

This is a video synopsis/summary of a panel discussion involving Ahmed Obeidat, MD, PhD; Riley Bove, MD; Stephen Krieger, MD; and Erin Longbrake, MD, PhD.

In this conversation, the speaker discusses how she presents NTCD20 therapies to patients in her practice. She emphasizes simplifying complex information and focusing on key points of efficacy and risks. She aims to empower patients by involving them in treatment decisions rather than overwhelming them with excessive material. Instead, she provides essential information such as dosing, administration methods, and considerations regarding insurance coverage. Real-world examples of patients' experiences on medication are used to illustrate the potential benefits of treatment and alleviate concerns. The speaker also acknowledges her bias towards early treatment initiation, ensuring transparency with patients about her perspective. This approach fosters informed decision-making and patient engagement in their healthcare journey.

Video synopsis is AI-generated and reviewed by NeurologyLive editorial staff.

Related Videos
Bruce Cree, MD
A panel of 3 experts on Alzheimer's disease
A panel of 3 experts on Alzheimer's disease
Video 6 - "Utilization of Neuroimaging in Alzheimer’s Disease"
Video 5 - "Contribution of Multiple Pathways to the Development of Alzheimer’s Disease"
© 2024 MJH Life Sciences

All rights reserved.